{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T08:12:25Z","timestamp":1789805545537,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5411,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1093\/annonc\/mdi096","type":"journal-article","created":{"date-parts":[[2005,1,25]],"date-time":"2005-01-25T01:24:19Z","timestamp":1106616259000},"page":"419-424","source":"Crossref","is-referenced-by-count":15,"title":["Sequential mitoxantrone\/prednisone followed by docetaxel\/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study"],"prefix":"10.1016","volume":"16","author":[{"given":"A.","family":"Font","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Garc\u00eda Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Areal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Constenla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Saladie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi096_bb0010","article-title":"Cancer Incidence, Mortality and Prevalence Worldwide, 5th edition","author":"Ferlay","year":"2001","journal-title":"IARC Cancerbase"},{"key":"10.1093\/annonc\/mdi096_bb0015","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1985.3.6.827","article-title":"A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma","volume":"3","author":"Eisenberger","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0020","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G","article-title":"Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer","volume":"371","author":"Yagoda","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi096_bb0025","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0030","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0035","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0040","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.1994.12.10.2005","article-title":"Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate","volume":"12","author":"Pienta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0045","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.1997.15.9.3156","article-title":"Phase II trial of 96-h paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer","volume":"15","author":"Hudes","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1008354600497","article-title":"Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma","volume":"10","author":"Kreiss","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0060","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2001.19.9.2509","article-title":"Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780","volume":"19","author":"Savarese","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0065","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/1078-0432.CCR-1021-03","article-title":"Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer","volume":"10","author":"Beer","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi096_bb0070","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0075","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0080","first-page":"8","article-title":"Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic","volume":"28","author":"Berry","year":"2001","journal-title":"metastatic carcinoma of the prostate. Semin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0085","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1023\/A:1012258723075","article-title":"Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer","volume":"12","author":"Beer","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0093-7754(01)90150-2","article-title":"Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer","volume":"28","author":"Copur","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000078328","article-title":"A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer","volume":"66","author":"Ferrero","year":"2004","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdi096_bb0100","first-page":"177a","article-title":"Preliminary results of a phase II randomized trial of docetaxel (D) estramustine (E) and prednisone (P)two schedulesversus mitoxantrone (M) and prednisone in patients with hormone refractory prostate cancer (HRPC)","volume":"21","author":"Oudard","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi096_bb0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi096_bb0115","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0120","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2004.07.190","article-title":"Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0125","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1200\/JCO.2001.19.8.2114","article-title":"Topotecan versus observation after cisplatin plus etoposide in extensive-stage-small-cell lung cancer: ET593 a phase III trial of the Eastern Cooperative Oncology Group","volume":"19","author":"Schiller","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0130","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.2000.18.4.840","article-title":"Phase I evaluation of sequential doxorubicin+gemcitabine then ifosfamide+paclitaxel+ cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract","volume":"18","author":"Dodd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi096_bb0135","first-page":"2371","article-title":"Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer","volume":"3","author":"Ellerhorst","year":"1997","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419478848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419478848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/3\/419\/378071\/mdi096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:00:26Z","timestamp":1582218026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419478848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0923753419478848"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi096","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}